{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:39:46Z","timestamp":1792067986586,"version":"4.4.0"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5R01DA056407"],"award-info":[{"award-number":["5R01DA056407"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA050771"],"award-info":[{"award-number":["K01DA050771"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Extended release buprenorphine injection (INJ\u2010BUP) has been available in the United States since 2018. INJ\u2010BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options. As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ\u2010BUP. Uptake of INJ\u2010BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ\u2010BUP for Medicaid beneficiaries since 2018, nationwide and by state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ\u2010BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T\u2010MSIS SUD) Data Books. Data sources are publicly available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of prescription fills for INJ\u2010BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186\u2009861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185\u2009000 in 2022 but uptake is much less than observed in other countries over shorter time periods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.16652","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:35:07Z","timestamp":1723782907000},"page":"2211-2215","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018\u20132022"],"prefix":"10.1111","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-6918","authenticated-orcid":false,"given":"Rachael K.","family":"Ross","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health Columbia University  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-7960","authenticated-orcid":false,"given":"Kara E.","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health Columbia University  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-4101","authenticated-orcid":false,"given":"Chelsea L.","family":"Shover","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Health Services Research, School of Medicine University of California Los Angeles  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.52965\/001c.37517"},{"key":"e_1_2_9_3_1","volume-title":"[cited 2023 Oct 7]. BRIXADI\u00ae (buprenorphine) Extended\u2010Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder","author":"braeburn","year":"2023"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175575"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15048"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13732"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.11398"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103788"},{"key":"e_1_2_9_9_1","first-page":"1","article-title":"Prolonged\u2010Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life","author":"Somaini L","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S180641"},{"key":"e_1_2_9_11_1","volume-title":"Medicaid coverage of medication\u2010assisted treatment for alcohol and opioid use disorders and of medication for the reversal of opioid overdose","author":"O'Brien P","year":"2018"},{"key":"e_1_2_9_12_1","volume-title":"Medicaid Behavioral Health Services: Injectable Buprenorphine for Medication Assisted Treatment (MAT)","author":"KFF","year":"2023"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000165"},{"key":"e_1_2_9_14_1","volume-title":"State drug utilization data","author":"Data.Medicaid.gov","year":"2023"},{"key":"e_1_2_9_15_1","volume-title":"Opioid Use Disorder (OUD) 1: Overarching Opioid Use Disorder","author":"Chronic Conditions Data Warehouse: Other Chronic Health, Mental Health, and Potentially Disabling Conditions","year":"2023"},{"key":"e_1_2_9_16_1","unstructured":"Interactive T\u2010MSIS SUD Data Book.2023. Available from:https:\/\/www.medicaid.gov\/medicaid\/data-systems\/macbis\/medicaid-chip-research-files\/transformed-medicaid-statistical-information-system-t-msis-analytic-files-taf\/index.html#sud"},{"key":"e_1_2_9_17_1","volume-title":"Treatment of SUD in Medicaid, 2021","author":"Becerra X","year":"2023"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104255"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111032"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26522"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000633"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.031"},{"key":"e_1_2_9_23_1","volume-title":"Medicaid prescriptions for extended\u2010release medications to treat opioid use disorder: state trends from 2011 to 2018 [internet]","author":"Clemans\u2010Cope L","year":"2020"},{"key":"e_1_2_9_24_1","volume-title":"State variation in Medicaid prescriptions for opioid use disorder from 2011 to 2018","author":"Clemans\u2010Cope L","year":"2019"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.01513"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.16652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T23:03:45Z","timestamp":1731711825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.16652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/add.16652"],"URL":"https:\/\/doi.org\/10.1111\/add.16652","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"2024-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}